REVBW - Revelation Biosciences, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

REVBW

REVELATION BIOSCIENCES, INC.

NASDAQ

$0.01

▲ UP 47.76% (0.00)

KEY STATISTICS

Market Cap$58.65 K

52w High$0.01

52w Low$0.01

Dividend Yield—

Frequency—

P/E—

Volume249

Shares Out.5.92M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

James Rolke

ABOUT

SECTOR

Healthcare

WENT PUBLIC

January 11, 2022

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.—

NOV

THU

PRICE

$0.01 ▲ UP 48.35% (+$73.38)

—

No price history available for REVBW over this range.

About Revelation Biosciences, Inc.

https://www.revbiosciences.com ↗

Revelation Biosciences, founded in 2019 in New York, develops immunologic therapeutics and diagnostics, including REVTx-99 for respiratory viruses, REVTx-200 as a vaccine adjunct, and REVDx-501 diagnostics.

INDUSTRY

Biotechnology

A PRODUCT REVELATION BIOSCIENCES, INC. IS KNOWN FOR

Gemini

Gemini's proprietary PHAD-based drug candidate is in clinical trials for AKI and CKD, with FDA approval pathway established, aiming to rebalance inflammation in kidney disease treatment.